Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients

Magdalena Meszaros, Régine Truchi, Denis Ouzan, Albert Tran, Marc Bourlière, Georges‐Philippe Pageaux

Open source

DOI
10.1002/hep.31909
Published
2021-06-16
Container
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/hep.31909,
  title = {Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients},
  author = {Magdalena Meszaros and Régine Truchi and Denis Ouzan and Albert Tran and Marc Bourlière and Georges‐Philippe Pageaux},
  year = {2021},
  journal = {Hepatology},
  doi = {10.1002/hep.31909},
  url = {https://doi.org/10.1002/hep.31909}
}

RIS

TY  - JOUR
TI  - Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients
AU  - Magdalena Meszaros
AU  - Régine Truchi
AU  - Denis Ouzan
AU  - Albert Tran
AU  - Marc Bourlière
AU  - Georges‐Philippe Pageaux
PY  - 2021
JO  - Hepatology
DO  - 10.1002/hep.31909
UR  - https://doi.org/10.1002/hep.31909
ER  - 

APA

Meszaros, M., Truchi, R., Ouzan, D., Tran, A., Bourlière, M., & Pageaux, G. (2021). Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients. Hepatology. https://doi.org/10.1002/hep.31909

Source records